Evidence map›Paper›PMID 32323779›Full record

ArticleOncology reports2020

Sulforaphane suppresses carcinogenesis of colorectal cancer through the ERK/Nrf2‑UDP glucuronosyltransferase 1A metabolic axis activation.

Qian Hao, Min Wang, Nuan-Xin Sun, Cheng Zhu, Ying-Min Lin, Cui Li, Fang Liu, Wen-Wen Zhu

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. NRF2 as a ferroptosis gatekeeper in colorectal cancer: implications for therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. The Role of NRF2 in Trinucleotide Repeat Expansion Disorders.Antioxidants (Basel, Switzerland) · 2024
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Qian HaoDepartment of Geriatric Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China.
Min WangDepartment of Geriatric Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China.
Nuan-Xin SunJiangxi Medical School, Nanchang University, Nanchang, Jiangxi 330031, P.R. China.
Cheng ZhuDepartment of Geriatric Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China.
Ying-Min LinDepartment of General Practice, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China.
Cui LiDepartment of General Practice, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China.
Fang LiuDepartment of Gastroenterology, Taian City Central Hospital, Taian, Shandong 271000, P.R. China.
Wen-Wen ZhuDepartment of Geriatric Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China.
Qilu Hospital of Shandong University · CNNanchang University · CNTaian City Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The long pre‑cancerous state of colorectal cancer (CRC) provides an opportunity to prevent the occurrence and development of CRC. The detoxification of CRC food‑borne carcinogenic heterocyclic amines is highly dependent on UDP glucuronosyltransferase 1A (UGT1A)‑mediated glucuronidation. Sulforaphane (SFN), a phytochemical, possesses antioxidant, anti‑inflammatory and anticarcinogenic effects on the prevention of CRC. Previous studies revealed that SFN upregulates the expression of UGT1A. The aim of the present study was to investigate the regulatory mechanism of SFN‑induced UGT1A upregulation and provide novel understanding on the basic research and chemoprevention of CRC. In the present study, the viability and proliferation of CRC cells (HT‑29 and SW480) treated with SFN were assessed by MTT, colony formation and EdU assays. Flow cytometry was used to detect the cell cycle arrest and apoptosis of cells treated with different concentrations of SFN. The motility of cells was determined by wound healing and Transwell assays. Nuclear factor, erythroid 2 like 2 (Nrf2) short hairpin RNA (shRNA) and negative control shRNA lentiviruses were used for cell transfection. Reverse transcription‑quantitative polymerase chain reaction and western blotting were employed to verify the role of Nrf2 in SFN‑induced UGT1A. HT‑29 and SW480 cells were divided into a control, an SFN and a PD98059 [an extracellular signal‑regulated kinase (ERK) inhibitor] + SFN group. Western blotting detected the protein levels of Nrf2 and UGT1A. Intracellular levels of reactive oxygen species (ROS) were detected using a reactive oxygen assay kit. The results revealed that SFN inhibits cell proliferation and colony formation, promotes apoptosis, and reduces the migratory ability of CRC cells. The phosphorylation of ERK induced by SFN promoted Nrf2 accumulation. Furthermore, a significant increase in the levels of UGT1A was observed, which coincided with SFN‑induced upregulation of Nrf2 levels in nuclear fractions. Pretreatment with PD58059 reversed the SFN‑induced subcellular translocation of Nrf2 and the expression of UGT1A. In addition, SFN‑induced high levels of ROS in CRC cells may be associated with the ERK signaling pathway. Collectively, these results indicated that SFN inhibited the proliferation of CRC cells and upregulated the expression of UGT1A in CRC cells via the ERK/Nrf2 signaling pathway.

Indexed as

Anticarcinogenic AgentsAntioxidantsApoptosisCell Cycle CheckpointsCell Line, TumorCell ProliferationColorectal NeoplasmsGlucuronosyltransferaseHumansIsothiocyanatesMAP Kinase Signaling SystemMitogen-Activated Protein Kinase 3NF-E2-Related Factor 2Reactive Oxygen SpeciesSulfoxidesUGT1A1 EnzymeAnticarcinogenic AgentsAntioxidantsGlucuronosyltransferaseIsothiocyanatesMAPK3 protein, humanMitogen-Activated Protein Kinase 3NFE2L2 protein, humanNF-E2-Related Factor 2Reactive Oxygen SpeciessulforaphaneSulfoxidesUGT1A1 Enzymechemopreventioncolorectal cancerERKNrf2sulforaphaneUGT1A

Identifiers

PMID32323779
PMCPMC7057772
OpenAlexW3004815991

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.